×
SciSparc Net Current Debt 2017-2024 | SPRC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
SciSparc net current debt from 2017 to 2024. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
SciSparc Net Current Debt 2017-2024 | SPRC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
SciSparc net current debt from 2017 to 2024. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$69.3B
Zoetis (ZTS)
$67.6B
Takeda Pharmaceutical (TAK)
$47B
Daiichi Sankyo, - (DSNKY)
$46.1B
BeOne Medicines - (ONC)
$33.7B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$20B
Merck (MKKGY)
$16.8B
Shionogi (SGIOY)
$15.5B
United Therapeutics (UTHR)
$14B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$10.8B
IPSEN (IPSEY)
$10.6B
Madrigal Pharmaceuticals (MDGL)
$8.3B
Corcept Therapeutics (CORT)
$7.7B
Grifols, S.A (GRFS)
$7.3B
Ionis Pharmaceuticals (IONS)
$6.9B
Stevanato Group S.p.A (STVN)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.3B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4.3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Hypermarcas (HYPMY)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.2B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B